Clinical trial
Safety and Tolerability of SPD503 and Psychostimulants in Children and…
NCT00151996 · Shire, Industry · Completed
Key facts
| NCT number | NCT00151996 |
|---|---|
| Title | Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Official title | A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | Methylphenidate + SPD503 (Guanfacine hydrochloride), Amphetamine + SPD503 |
| Enrollment | 75 |
| Start date | Aug 16, 2004 |
| Primary completion | Dec 27, 2004 |
| Completion | Dec 27, 2004 |
| First posted | Sep 9, 2005 |
| Last update posted | Jun 10, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: